GAMBACORTI PASSERINI CARLO

Posizione organizzativa: 
Ruolo: 
professore ordinario
Settore scientifico disciplinare: 
MALATTIE DEL SANGUE (MED/15)
Telefono: 
0264488362
0264488057
Stanza: 
U08, Piano: P04, Stanza: 4041
Via Cadore, 48 - 20900 MONZA
U8, Piano: IV, Stanza: 4-12
Via Cadore, 48 - 20900 MONZA

Didattica

Pubblicazioni

  • Hehlmann, R., Cortes, J., Zyczynski, T., Gambacorti-Passerini, C., Goldberg, S., Mauro, M., et al. (2019). Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. AMERICAN JOURNAL OF HEMATOLOGY, 94(1), 46-54. Dettaglio
  • Menotti, M., Ambrogio, C., Cheong, T., Pighi, C., Mota, I., Cassel, S., et al. (2019). Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. NATURE MEDICINE, 25(1), 130-140. Dettaglio
  • Michelozzi, I., Granata, V., DE PONTI, G., Alberti, G., Tomasoni, C., Antolini, L., et al. (2019). Acute myeloid leukaemia niche regulates response to L-asparaginase. BRITISH JOURNAL OF HAEMATOLOGY, 186(3), 420-430. Dettaglio
  • Magistroni, V., Mauri, M., D'Aliberti, D., Mezzatesta, C., Crespiatico, I., Nava, M., et al. (2019). De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. HAEMATOLOGICA. Dettaglio
  • Gambacorti Passerini, C., Orlov, S., Zhang, L., Braiteh, F., Huang, H., Esaki, T., et al. (2018). Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. AMERICAN JOURNAL OF HEMATOLOGY, 93(5), 607-614. Dettaglio